William C. Roell

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun, Kyle W. Sloop, Corina Loghin et al. · Molecular Metabolism · 2018 · 822 citations · Full text

Medicine, Endocrinology, Pharmacology +17

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022 · 276 citations · Full text

Medicine, Endocrinology, Pharmacology +17

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

Ricardo J. Samms, Michael E. Christe, Kyla Collins et al. · Journal of Clinical Investigation · 2021 · 227 citations · Full text

Medicine, Endocrinology, Pharmacology +17

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

Jonathan M. Wilson, Amir Nikooienejad, Deborah A. Robins et al. · Diabetes Obesity and Metabolism · 2020 · 157 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids

Yan Chen, Thomas G. Pottanat, Robert W. Siegel et al. · Journal of Lipid Research · 2020 · 148 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16